$-0.29 EPS Expected for Proteon Therapeutics, Inc. (PRTO)

October 13, 2018 - By Louis Casey

Proteon Therapeutics, Inc. (NASDAQ:PRTO) LogoInvestors sentiment decreased to 0.86 in 2018 Q2. Its down 0.02, from 0.88 in 2018Q1. It dropped, as 6 investors sold Proteon Therapeutics, Inc. shares while 1 reduced holdings. 2 funds opened positions while 4 raised stakes. 7.28 million shares or 0.08% more from 7.27 million shares in 2018Q1 were reported.
Mpm Asset Mngmt Limited Liability Corporation has 0.93% invested in Proteon Therapeutics, Inc. (NASDAQ:PRTO) for 983,381 shares. Blackrock Inc has 30,370 shares. Ra Cap Ltd accumulated 1.34M shares or 0.21% of the stock. Acadian Asset Ltd Liability Com holds 0% of its portfolio in Proteon Therapeutics, Inc. (NASDAQ:PRTO) for 5,328 shares. The Pennsylvania-based Vanguard Grp has invested 0% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Abingworth Limited Liability Partnership reported 2.77% of its portfolio in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Mariner Ltd Com reported 10,000 shares. Dimensional Fund Advisors Lp stated it has 0% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Panagora Asset Mgmt Incorporated invested in 15,441 shares. Perceptive Advsr Ltd Llc owns 334,116 shares. Renaissance Technologies Ltd Limited Liability Company stated it has 0% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Royal National Bank Of Canada holds 0% or 3,825 shares. Deutsche Financial Bank Ag reported 36,388 shares. Northern Trust Corp has invested 0% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Geode Cap Mgmt Ltd Com owns 32,340 shares.

Analysts expect Proteon Therapeutics, Inc. (NASDAQ:PRTO) to report $-0.29 EPS on November, 6.They anticipate $0.79 EPS change or 73.15 % from last quarter’s $-1.08 EPS. After having $-0.28 EPS previously, Proteon Therapeutics, Inc.’s analysts see 3.57 % EPS growth. The stock decreased 0.63% or $0.01 during the last trading session, reaching $1.58. About 63,859 shares traded or 9.08% up from the average. Proteon Therapeutics, Inc. (NASDAQ:PRTO) has risen 59.26% since October 14, 2017 and is uptrending. It has outperformed by 43.64% the S&P500.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. The company has market cap of $28.01 million. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. It currently has negative earnings.

Another recent and important Proteon Therapeutics, Inc. (NASDAQ:PRTO) news was published by Benzinga.com which published an article titled: “The Daily Biotech Pulse: Affimed’s Cancer Drug Placed On Clinical Hold, Celgene’s Positive Scalp Psoriasis Trial” on October 09, 2018.

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>